Aminoguanidine administered during the induction of oral tolerance alters the systemic response of the tolerised rats

Cellular Immunology
Liliana G FrancoFabian Benencia

Abstract

Herewith we investigated the role of nitric oxide synthase (NOS)-II in the establishment of oral tolerance induced by low antigen dose. To accomplish this, we used a rat model of oral tolerance induced by intragastric administration of low doses of ovalbumin (OVA). NOS-II was inhibited in vivo during the onset of tolerance by intraperitoneal (i.p.) treatment with aminoguanidine (AMG), a selective NOS-II inhibitor. Four experimental groups were generated: (TOL), tolerised rats, receiving OVA but no AMG; (TAG), rats tolerised with OVA and simultaneously receiving AMG i.p.; (CAG), controls treated with AMG but no oral antigen; and (CONT), controls receiving neither OVA nor AMG treatment. The state of oral tolerance was evaluated in all groups by analysing several immune parameters upon subcutaneous administration of OVA in Freund's complete adjuvant. First, we were able to determine that NOS-II inhibition altered the TH1/TH2 balance in tolerised rats, driving the TH2 anti-OVA response in TOL rats towards TH1 in TAG animals, which showed enhanced delayed hypersensitivity responses. Second, splenocyte cultures from TAG rats showed lower levels of IL-10 production compared to TOL samples as determined by ELISA analysis. Last, we dete...Continue Reading

References

Mar 1, 1994·The Biochemical Journal·R G Knowles, S Moncada
Jan 10, 1995·Archives of Biochemistry and Biophysics·D J Wolff, A Lubeskie
Feb 23, 1996·Biochemical Pharmacology·G J Southan, C Szabó
Oct 1, 1995·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·M A De Groote, F C Fang
Jan 1, 1997·Annual Review of Immunology·J MacMickingC Nathan
Nov 24, 1999·Inflammation Research : Official Journal of the European Histamine Research Society ... [et Al.]·B O Nilsson
Dec 3, 1999·Immunology·F Benencia, M C Courreges
Aug 22, 2001·European Journal of Pharmacology·K H PehF L Pearce
May 3, 2003·Virology·Fabián BenenciaErnesto Jorge Massouh
Jun 18, 2003·Trends in Immunology·Vincenzo BrontePaola Zanovello
May 4, 2004·Journal of Medical Virology·Gisela GambaFabian Benencia
Oct 27, 2004·Journal of Autoimmunity·Patricia A GonnellaHoward L Weiner
Feb 1, 2005·Annals of the New York Academy of Sciences·Manuela BattagliaMaria-Grazia Roncarolo
Aug 2, 2005·Nature Reviews. Immunology·Vincenzo Bronte, Paola Zanovello
Feb 2, 2006·European Journal of Pharmacology·Cezmi A Akdis, F Estelle R Simons
May 4, 2006·Current Opinion in Allergy and Clinical Immunology·Stephan Strobel, Allan McI Mowat
Aug 22, 2006·Inflammation & Allergy Drug Targets·Ana M C Faria, Howard L Weiner
Sep 19, 2007·Proceedings of the National Academy of Sciences of the United States of America·Wanda NiedbalaFoo Y Liew
Mar 28, 2008·Immunological Reviews·Ilaria MarigoVincenzo Bronte

❮ Previous
Next ❯

Related Concepts

Related Feeds

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.